Understanding secondary hypogammaglobulinemia and its implications for cancer prognosis in children: A retrospective cohort study

Dra Guzmán, Dra Villamil, Dra Martínez Betancur, Dra Arias, Jacobo Triviño-Arias, Jessica Largo, Dra Lotero, Dr Franco, Dra Castro , Dra Rodríguez, Dra Urcuqui, Dr Medina , Dra Olaya, .

Keywords: agammaglobulinemia, neoplasms, pediatrics, child

Abstract

Introduction. Immunodeficiencies are disturbances in the immune system that can affect cell function, quantity, or both. They can be either primary, associated with genetic defects, or secondary, linked to external factors such as hemato-oncological conditions. Secondary immunodeficiencies can lead to the initiation, reactivation, or acceleration of latent, residual, or active infections, which are the leading cause of mortality.
Objective. To elucidate the occurrence and clinical characteristics of hypogammaglobulinemia in pediatric oncology patients in a high-complexity hospital in
Colombia between January 2020 and December 2022.
Materials and methods. We conducted an observational study with patients under 18 years old with a cancer diagnosis, serum immunoglobulins measurements at the time of the diagnosis, and later follow-up during treatment.
Results. We included 133 patients with a median age of eight years. Based on local guidelines of immunoglobulin levels for age, all patients had normal values at the time of cancer diagnosis. In the follow-up, the most significant reduction among all ages was for IgA and was related to infections and death.
Conclusions. Our findings highlight the importance of measuring immunoglobulin levels at the time of the cancer diagnosis, as hypogammaglobulinemia may be linked to a poorer prognosis. Early detection could potentially improve patient outcomes.

Downloads

References

Alsina L, De Lara M, Santos-Díez Vázquez L. Manejo de las inmunodeficiencias secundarias en pediatría. Accessed: June 17, 2024. Available at: www.aeped.es/protocolos/

Organización Panamericana de la Salud. Día Internacional contra el Cáncer Infantil. 2022. Accessed: June 17, 2024. Available at: https://www.paho.org/es/campanas/diainternacional-contra-cancer-infantil-2022

Organización Panamericana de la Salud. Mes de Concientización del Cáncer Infantil - Septiembre 2023. Accessed: June 17, 2024. Available at: https://www.paho.org/es/campanas/mes-concientizacion-cancer-infantil-septiembre-2023

Sánchez-Ramón S, Bermúdez A, González-Granado LI, Rodríguez-Gallego C, Sastre A, Soler-Palacín P, et al. Primary and secondary immunodeficiency diseases in oncohaematology: Warning signs, diagnosis, and management. Front Immunol. 2019;10. https://doi.org/10.3389/fimmu.2019.00586

Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: An overview. Ann Allergy Asthma Immunol. 2021;127:617-26. https://doi.org/10.1016/j.anai.2021.08.413

Borte M, Hanitsch LG, Mahlaoui N, Fasshauer M, Huscher D, Speletas M, et al. Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: The FIGARO Study. J Clin Immunol. 2023;43:1259-71. https://doi.org/10.1007/s10875-023-01470-2

Derpoorter C, Bordon V, Laureys G, Haerynck F, Lammens T. Genes at the crossroad of primary immunodeficiencies and cancer. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.02544

Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34:121-32. https://doi.org/10.1002/hon.2323

Jaffe EF, Lejtenyi MC, Noya FJD, Mazer BD. Secondary hypogammaglobulinemia. Immunol Allergy Clin North Am. 2001;21:141-63. https://doi.org/10.1016/S0889-8561(05)70197-1

Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396-404. https://doi.org/10.1016/j.ijantimicag.2010.11.027

Dilley M, Wangberg H, Noone J, Geng B. Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities. Allergy Asthma Proc. 2021;42:78-86. https://doi.org/10.2500/aap.2021.42.200113

Jolliff CR, Cost KM, Stivrins PC, Grossman PP, Nolte CR, Franco SM, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem. 1982;28:126-8.

How to Cite
1.
Guzmán AL, Villamil I, Martínez-Betancur S, Arias-Valderrama O, Triviño-Arias J, Largo J, et al. Understanding secondary hypogammaglobulinemia and its implications for cancer prognosis in children: A retrospective cohort study. Biomed. [Internet]. 2024 Dec. 23 [cited 2025 Apr. 9];44(Sp. 2):191-7. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/7584

Some similar items:

Published
2024-12-23
Article metrics
Abstract views373
Galley vies97
PDF Views97
HTML views0
Other views0
Crossref Cited-by logo
QR Code